Tekcapital up almost 40% after securing first MicroSalt customer
Anita Riotta
Company News- 3 min read
08:00, 23rd April 2019

Tekcapital (TEK) FOLLOW informed investors today that its portfolio company Salarius has been significantly ramping up activity. 

Salarius, as both developer and manufacturer, has launched production of MicroSalt, the company’s new, proprietary low sodium salt. 

Salarius has not only begun production of its product, it has also found a first customer to incorporate MicroSalt into their snack food business. While the precise company was not named, the news released by Tekcapital confirmed it is an American company.

Tekcapital saw their share prices jump over 30% in reaction to their announcement.

For the intellectual property company, MicroSalt’s distinguishing feature is precisely its small,  salt particles-- about one hundred times smaller than typical table salt-- that use a large surface area-to-volume ratio to generate a salty taste while using significantly less salt.

And this tiny grain can, in Salarius’ view, make a big difference. 

Decreasing the public’s sodium intake would aid the efforts to curtail heart disease, which in the UK alone accounts for over a quarter, 26%, of deaths in the UK. And, according to the National Academies of Sciences, Engineering and Medicine, “There is sufficient evidence to characterize the relationship between sodium intake and risk of chronic disease.”

So, with such need comes a market. Future Market Insights has estimated that the sodium reduction market will be worth $1.76 billion by 2025 with a CAGR of 11.8%.

Victor Hugo Manzanilla, CEO of Salarius, commented on the news: “We know that ‘flavor is everything’ in the snacks industry, so we developed a salt that does not compromise on flavor, while simultaneously addressing the critical need to reduce sodium.  

Consumers are aware of the need to eat healthier and select better-for-you options when available. MicroSalt® will help manufacturers worldwide take a leadership role in reducing cardiovascular disease by enhancing the nutritional content of their products.”

We sat down with Dr. Clifford Gross, CEO of Tekcapital, to learn more about how the company's 'invention discovery network' finds, builds, and commercializes ideas. Watch here

For more news and updates on Tekcapital: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles